Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00829777 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects
A Phase 1 study, sponsored by California Pacific Medical Center Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00829777: Completed Phase 1 study, sponsored by California Pacific Medical Center Research Institute.
NCT00829777 is a Phase 1 study that has completed, run by California Pacific Medical Center Research Institute. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00829777, a Phase 1 study, has completed, sponsored by California Pacific Medical Center Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of intravenous 6β-Naltrexol administered to opiate dependent subjects
Interventions
- DRUG 6β-Naltrexol escalating doses from 0.05-0.5 mg IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
What the finished NCT00829777 record still lists
NCT00829777 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which 6β-Naltrexol escalating doses from 0.05-0.5 mg IV is the first listed.
NCT00829777 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00829777 about?
NCT00829777 is a clinical study titled "Safety Study of Intravenous 6β-Naltrexol (AIKO-150) in Opioid-Dependent Subjects". The purpose of this study is to evaluate the safety and efficacy of intravenous 6β-Naltrexol administered to opiate dependent subjects
What is the current status of trial NCT00829777?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-03. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00829777?
The interventions under investigation include: 6β-Naltrexol escalating doses from 0.05-0.5 mg IV (DRUG).
Who is sponsoring clinical trial NCT00829777?
This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00829777's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia